Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,411 across all filing types
Latest filing 2026-06-04 Share Issue/Capital Cha…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Sanofi lance son plan mondial 2026 d’actionnariat salarié
Share Issue/Capital Change Classification · 95% confidence The document is a press release announcing Sanofi’s global employee shareholding plan (“Action 2026”), detailing the terms of a new share issuance reserved for employees, subscription price, discount, number of new shares, legal and subscription conditions, and admission to trading of the new shares. This is a capital change announcement specifically regarding a share issue. Therefore, it falls under Share Issue/Capital Change (SHA).
2026-06-04 French
Press Release: Sanofi launches 2026 global employee stock purchase plan
Share Issue/Capital Change Classification · 95% confidence The document is a press release announcing Sanofi’s global employee share purchase plan, detailing the terms of a capital increase reserved for employees (subscription price, number of new shares, matching shares, admission to trading). This is an announcement of a new share issue/capital change, matching category “Share Issue/Capital Change” (SHA).
2026-06-04 English
SD
Regulatory Filings Classification · 85% confidence The document is an SEC Form SD (“Specialized Disclosure Report”) used for conflict minerals disclosure under Rule 13p-1 of the Securities Exchange Act. It is a regulatory compliance filing detailing sourcing and due diligence processes, rather than an annual or interim financial report, call transcript, earnings release, or other specific category. It does not announce a report publication, but is itself the compliance report. Therefore it best fits under the fallback category for miscellaneous regulatory compliance filings: Regulatory Filings (RNS).
2026-05-28 English
Communiqué de presse : Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3
Regulatory Filings Classification · 88% confidence The document is a Sanofi press release (“Communiqué de presse”) announcing FDA priority review of a new drug application for venglustat, describing clinical trial results and regulatory designations. It contains no financial data, no summary financial results, no management changes, no dividend or share issue, and does not itself present a financial or audit report. It is a general regulatory/market announcement that does not fit any specialized category, so it should be classified as a general Regulatory Filing (RNS).
2026-05-28 French
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Regulatory Filings Classification · 88% confidence The document is a corporate press release announcing that the FDA has accepted Sanofi’s new drug application for priority review of venglustat. It contains clinical study details, regulatory designations, and forward-looking statements, but it is not an earnings release, financial report, management discussion, or formal SEC filing of results. It is a general corporate announcement/regulatory update. None of the specific categories (earnings release, IR, 10-K, M&A, etc.) fit. Therefore, by fallback, this is classified as a general regulatory/business announcement under Regulatory Filings (RNS).
2026-05-28 English
6-K
Report Publication Announcement Classification · 85% confidence The document is a Form 6-K, a SEC filing by a foreign private issuer, stating that a press release is attached as Exhibit 99.1 and incorporated by reference. It does not include substantive financial statements or analysis itself but merely announces the publication of a press release. Under the “menu vs meal” rule, this is an announcement of a report (the press release), not the report itself. Therefore, it should be classified as a Report Publication Announcement.
2026-05-27 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.